Suscribirse

From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era - 13/01/23

Doi : 10.1016/j.biopha.2022.114208 
Ganggang Miao a, b, 1, Zhiqiang Chen c, 1, Hengsong Cao b, 1, Wenhao Wu d, 1, Xi Chu e, 1, Hanyuan Liu b, Leyao Zhang d, Hongfei Zhu d, Hongzhou Cai f, , Xiaolan Lu g, , Junfeng Shi h, i, , Yuan Liu j, , Tingting Feng k,
a Department of General Surgery, The People’s Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang, China 
b Department of General Surgery, The Affiliated Nanjing Hospital of Nanjing Medical University, Nanjing, China 
c Department of Nuclear Medicine, The First Affiliated Hospital of Suzhou University, Suzhou, China 
d Department of Clinical Medicine, Nanjing Medical University The First School of Clinical Medicine, Nanjing, China 
e Department of Radiology, Nanjing Medical University The Fourth School of Clinical Medicine, Nanjing, China 
f Department of Urology, Jiangsu Cancer Hospital &The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research, Nanjing, China 
g Department of Clinical laboratory, Canglang Hospital of Suzhou, Suzhou, China 
h Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China 
i Department of Molecular and Celluar Biochemistry, Markey Cancer Center, University of Kentucky, Lexington, KY, USA 
j Department of Infectious Disease,The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China 
k Jiangsu Key Laboratory of Infection and Immunity, Institute of Biology and Medical Sciences, Soochow University, Suzhou, China 

Corresponding authors.⁎⁎Corresponding author at: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.Department of Oncology, Nanjing First Hospital, Nanjing Medical UniversityNanjingChina

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

The COVID-19 pandemic has affected millions of people and posed an unprecedented burden on healthcare systems and economies worldwide since the outbreak of the COVID-19. A considerable number of nations have investigated COVID-19 and proposed a series of prevention and treatment strategies thus far. The pandemic prevention strategies implemented in China have suggested that the spread of COVID-19 can be effectively reduced by restricting large-scale gathering, developing community-scale nucleic acid testing, and conducting epidemiological investigations, whereas sporadic cases have always been identified in numerous places. Currently, there is still no decisive therapy for COVID-19 or related complications. The development of COVID-19 vaccines has raised the hope for mitigating this pandemic based on the intercross immunity induced by COVID-19. Thus far, several types of COVID-19 vaccines have been developed and released to into financial markets. From the perspective of vaccine use in globe, COVID-19 vaccines are beneficial to mitigate the pandemic, whereas the relative adverse events have been reported progressively. This is a review about the development, challenges and prospects of COVID-19 vaccines, and it can provide more insights into all aspects of the vaccines.

El texto completo de este artículo está disponible en PDF.

Graphical Abstract




ga1

El texto completo de este artículo está disponible en PDF.

Highlights

COVID-19 and immune system.
The Evolution of COVID-19 vaccines.
Classification of vaccines.
Adverse reactions of vaccines.
Vaccination strategies.
The VOCs of COVID-19 and the second-generation vaccines.

El texto completo de este artículo está disponible en PDF.

Keywords : COVID-19, Vaccine, Complications, Contraindications, Adverse reactions


Esquema


© 2023  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 158

Artículo 114208- février 2023 Regresar al número
Artículo precedente Artículo precedente
  • Bioactivities and mechanism of action of securinega alkaloids derivatives reported prior to 2022
  • Wen Hou, Hao Huang, Xue-Qiang Wu, Jin-Xia Lan
| Artículo siguiente Artículo siguiente
  • LDHA as a regulator of T cell fate and its mechanisms in disease
  • Maosha Dai, Li Wang, Juexi Yang, Jiayi Chen, Xiaoke Dou, Rui Chen, Yangyang Ge, Yun Lin

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.